IRLAB Therapeutics AB (FRA:6IRA) E10: €-0.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6IRA IRLAB Therapeutics AB FRA:6IRA
41 GF Score
Price €0.12
GF Value €1.10
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB E10?

IRLAB Therapeutics AB FRA:6IRA +2.72% 41 E10 is €-0.16 as of Mar. 2026. GuruFocus rates FRA:6IRA with a GF Score™ of 41/100 and a GF Value™ of €1.10 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

IRLAB Therapeutics AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.16 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-18), IRLAB Therapeutics AB's current stock price is €0.121. IRLAB Therapeutics AB's E10 for the quarter that ended in Mar. 2026 was €-0.16. IRLAB Therapeutics AB's Shiller PE Ratio of today is .


IRLAB Therapeutics AB  (FRA:6IRA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


IRLAB Therapeutics AB E10 Related Terms


IRLAB Therapeutics AB E10 Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB E10 Chart

IRLAB Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.17

IRLAB Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.12 -0.15 -0.17 -0.16

FRA:6IRA vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, IRLAB Therapeutics AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Shiller PE Ratio falls into.


FRA:6IRA
41GF Score
IRLAB Therapeutics AB FRA:6IRA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRLAB Therapeutics AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IRLAB Therapeutics AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.01/133.5600*133.5600
=0.010

Current CPI (Mar. 2026) = 133.5600.

IRLAB Therapeutics AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.025 101.019 -0.033
201609 -0.040 101.138 -0.053
201612 -0.054 102.022 -0.071
201703 -0.038 102.022 -0.050
201706 -0.028 102.752 -0.036
201709 -0.056 103.279 -0.072
201712 -0.034 103.793 -0.044
201803 -0.040 103.962 -0.051
201806 -0.057 104.875 -0.073
201809 -0.007 105.679 -0.009
201812 -0.041 105.912 -0.052
201903 -0.039 105.886 -0.049
201906 -0.064 106.742 -0.080
201909 -0.045 107.214 -0.056
201912 -0.060 107.766 -0.074
202003 -0.036 106.563 -0.045
202006 -0.048 107.498 -0.060
202009 -0.049 107.635 -0.061
202012 -0.036 108.296 -0.044
202103 -0.035 108.360 -0.043
202106 -0.047 108.928 -0.058
202109 0.213 110.338 0.258
202112 -0.040 112.486 -0.047
202203 -0.049 114.825 -0.057
202206 -0.045 118.384 -0.051
202209 -0.039 122.296 -0.043
202212 -0.054 126.365 -0.057
202303 -0.095 127.042 -0.100
202306 -0.069 129.407 -0.071
202309 -0.058 130.224 -0.059
202312 -0.055 131.912 -0.056
202403 -0.061 132.205 -0.062
202406 -0.012 132.716 -0.012
202409 -0.053 132.304 -0.054
202412 -0.009 132.987 -0.009
202503 -0.058 132.825 -0.058
202506 -0.055 133.699 -0.055
202509 -0.021 133.480 -0.021
202512 -0.026 133.390 -0.026
202603 0.010 133.560 0.010

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.16 mean?
IRLAB Therapeutics AB (FRA:6IRA) has a E10 of €-0.16 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on IRLAB Therapeutics AB and its competitors.
Is IRLAB Therapeutics AB's E10 too high?
IRLAB Therapeutics AB's current E10 is €-0.16. Overall, IRLAB Therapeutics AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's E10 compare to VRTX and REGN?
IRLAB Therapeutics AB's E10 of €-0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on IRLAB Therapeutics AB and its competitors. IRLAB Therapeutics AB's current E10 is €-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (FRA:6IRA) is currently considered Possible Value Trap. The stock's GF Value™ is €1.10, compared to a current price of €0.12 — trading 89% below its estimated fair value. The current E10 is €-0.16. IRLAB Therapeutics AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For IRLAB Therapeutics AB (FRA:6IRA), the current E10 is €-0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (FRA:6IRA) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of €0.12 is trading 89% below its estimated GF Value™ of €1.10. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for FRA:6IRA:

  • E10: €-0.16
  • GF Value™: €1.10 vs. price of €0.12 (89% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the FRA:6IRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IRLAB Therapeutics AB Business Description

Other Exchanges IRLAB A:Sweden
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
41GF Score

Get the complete analysis for FRA:6IRA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€1.10
GF Value